JPRN-jRCTc030190195进行中（未招募）1 期
Treatment with chemotherapy and dendritic cells pulsed with WT1 peptides for pancreatic cancer. - WT1 based chemoimmunotherapy
Koido Shigeo0 个研究点目标入组 10 人开始时间: 2020年1月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Human leukocyte antigen (HLA)-A*2402, A*0201, A*0206, HLA-DR (DRB1*0101, DRB1*0405, DRB1*0802, DRB1*0803, DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DRB5*0102), HLA-DP (DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901), or HLA-DQ(DQB1*0301, DQB1*0302, DQB1*0401, DQB1*0501, DQB1*0601, DQB1*0602-positive patients.
- •Patients with histologically or cytologically confirmed locally advanced or metastatic pancreatic cancer, or recurrent disease after surgery.
- •Patients with ages between 20 and 75 years.
- •Karnofsky performance status (KPS) of 80% to 100%.
- •Patients with a KPS of 70% were also included but only if KPS was decreased by poorly controlled cancerous pain at enrollment.
- •Patients had adequate hematologic, hepatic, and renal function.
- •Patients had a life expectancy of at least 3 months.
- •All patients provided written informed consent.
排除标准
- •The exclusion criteria were pregnancy, serious infections, severe underlying disease, severe allergic disease, and a judgment of unsuitability by the principal investigator.
研究者
相似试验
招募中
1 期
eoantigen based chemoimmunotherapyadvanced pancreatic cancerpancreatic cancer, neoantigen, dendritic cell, cancer vaccinesJPRN-jRCTc030190081Koido Shigeo10
已完成
不适用
Treatment with standard chemotherapy and dendritic cells pulsed with WT1 peptides for pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000032386The Jikei University School of Medicine, Kashiwa Hospital, Division of Gastroenterology & Hepatology, Department of Internal Medicine10
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12
未知
1 期
Dendritic cell therapy and intratumor dendritic cell injection therapy using Tumor associated antigen or tumor lysate for patients with advanced and recurrent canceradvanced and recurrent cancerJPRN-UMIN000000775Fukushima Medical University25
已完成
1 期
Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00049218H. Lee Moffitt Cancer Center and Research Institute56